Post-Transplant Drug Therapy Improved Older Patient Survival
Researchers compared two common prevention methods for graft-versus-host disease in patients aged 60 and older.
Updated on Oct. 6, 2026 in Cancer
Live Poll
Does current medical research provide sufficient guidance for transplant treatment choices in older adults?
A study analyzing 7,507 patients who underwent stem cell transplants between 2016 and 2022 compared two primary methods for preventing graft-versus-host disease (GvHD). The findings offer new insight into which prophylaxis approach better supports survival outcomes in older adults.
Why it matters
Determining the most effective GvHD prophylaxis is essential for older adults, as the optimal treatment approach has historically remained uncertain. This study helps clinicians refine care strategies for patients aged 60 and older undergoing reduced-intensity conditioning.
This retrospective analysis of EBMT registry data evaluated 7,507 patients aged 60 or older who received reduced-intensity conditioning transplants. Researchers found that post-transplant cyclophosphamide (PTCy) improved progression-free survival in matched sibling donors over age 65 and overall survival in matched unrelated donor recipients, compared to anti-thymocyte globulin (ATG).
The players
EBMT (European Society for Blood and Marrow Transplantation)
An international scientific society that maintains a large registry of stem cell transplant data to improve patient outcomes.
The details
The study compared two common pharmacological interventions used to prevent graft-versus-host disease, a condition where donor immune cells attack the recipient's tissues. Researchers examined outcomes from peripheral blood stem cell allo-HCT procedures to see how PTCy and ATG influence recovery and survival. While PTCy showed advantages in specific sibling and unrelated donor groups, outcomes for mismatched unrelated donor transplants did not differ significantly between the two drug protocols.
Timeline
Data collection for this study spanned from 2016 to 2022.
Health Landscape
This study leverages the EBMT registry to clarify treatment protocols for aging populations who are increasingly eligible for stem cell transplants. It follows the broader medical trend of optimizing reduced-intensity conditioning regimens to improve post-transplant survival in patients over 60.
Patients preparing for a transplant should discuss GvHD prophylaxis options and their specific survival data with their hematologist or transplant team. It is worth asking your doctor which drug protocol is best suited for your donor type and age group based on current institutional research.
The takeaway
Selecting the right GvHD prophylaxis is a critical step in improving transplant outcomes for older adults. When preparing for this procedure, engage your care team in a conversation about the comparative benefits of current drug therapies tailored to your specific donor profile.
Further reading
For more on evolving treatment strategies, see our coverage of Cancer.
Source note: This article includes information reported by Nature.
Live Poll
Does current medical research provide sufficient guidance for transplant treatment choices in older adults?
